ADAM17 and ovarian carcinoma: Primary human NK cells were treated with TAB16 or TAB16/15 and evaluated for proliferation by cell dilution dye, ADAM17 blocking, activation marker expression, and cytotoxicity against ovarian cancer cell lines in real-time by IncuCyte assays.<h4>Results</h4>The TAB16 bispecific engager targeted NK cells and blocked ADAM17.